TiGenix secures Spanish reimbursement for ChondroCelect

The Spanish Health Authority has informed TiGenix that its cartilage repair therapy, ChondroCelect, will obtain national reimbursement in Spain. The company obtained national reimbursement in the Netherlands in 2012 and will continue working to obtain national reimbursement in other European countries later in 2013.

Currently, ChondroCelect is the first and the only cell therapy that has been granted market authorisation by the EU in accordance with the Advanced Therapy Medicinal Product regulation.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: Spain, Spain, Spain, Spain

Access all of our latest analysis, data and forecasts - request a trial